Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mDCF in Gastric and Gastroesophageal Junction Adenocarcinoma
NCT00515411Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2006
- Primary completion
- Oct 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cisplatin, fluorouracil, trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2006; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00515411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515411.